Cite
HARVARD Citation
Wierda, W. et al. (2021). Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of clinical oncology. 39 (34), pp. 3853-3865. [Online].